Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Armitage
James N
JN
Clinical Effectiveness Unit, The Royal College of Surgeons of England, and The Institute of Urology and Nephrology, University College London, London, UK.
Emberton
Mark
M
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D012307:Risk Factors; D014555:Urination Disorders / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin